

Maria Ochoa de Olza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3566445/publications.pdf>

Version: 2024-02-01

21
papers

719
citations

933447

10
h-index

940533

16
g-index

21
all docs

21
docs citations

21
times ranked

1177
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133.	9.4	165
2	Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. <i>Lancet Oncology</i> , The, 2020, 21, e419-e430.	10.7	128
3	The expanding role of immunotherapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 74-86.	7.7	100
4	A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. <i>Human Gene Therapy</i> , 2019, 30, 352-364.	2.7	66
5	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors. , 2020, 8, e000530.		54
6	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	7.3	54
7	OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 460-472.	7.0	48
8	Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?. <i>Clinical Cancer Research</i> , 2019, 25, 3210-3219.	7.0	35
9	Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138.	3.6	22
10	High versus low dose irradiation for tumor immune reprogramming. <i>Current Opinion in Biotechnology</i> , 2020, 65, 268-283.	6.6	13
11	A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3060-3060.	1.6	11
12	The Personalization of Therapy: Molecular Profiling Technologies and Their Application. <i>Seminars in Oncology</i> , 2015, 42, 775-787.	2.2	6
13	PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. <i>Cancer Management and Research</i> , 2020, Volume 12, 10251-10260.	1.9	5
14	A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to melanoma patients. <i>Human Gene Therapy Clinical Development</i> , 2018, , .	3.1	3
15	Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155.		3
16	A promising platform for predicting toxicity. <i>ELife</i> , 2021, 10, .	6.0	3
17	Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (tx) as predictor of clinical benefit (ClinBen) in early trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2572-2572.	1.6	2
18	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 168-178.	2.8	1

#	ARTICLE	IF	CITATIONS
19	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. Journal of Clinical Oncology, 2021, 39, 2533-2533.	1.6	0
20	Active surveillance before sequential targeted therapy in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, e15582-e15582.	1.6	0
21	Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.. Journal of Clinical Oncology, 2017, 35, 2581-2581.	1.6	0